Miles Prince - Profile on Academia.edu (original) (raw)
Papers by Miles Prince
Cancers
The association between smoking and alcohol consumption and follicular lymphoma (FL) incidence an... more The association between smoking and alcohol consumption and follicular lymphoma (FL) incidence and clinical outcome is uncertain. We conducted a population-based family case-control study (709 cases: 490 controls) in Australia. We assessed lifetime history of smoking and recent alcohol consumption and followed-up cases (median = 83 months). We examined associations with FL risk using unconditional logistic regression and with all-cause and FL-specific mortality of cases using Cox regression. FL risk was associated with ever smoking (OR = 1.38, 95%CI = 1.08–1.74), former smoking (OR = 1.36, 95%CI = 1.05–1.77), smoking initiation before age 17 (OR = 1.47, 95%CI = 1.06–2.05), the highest categories of cigarettes smoked per day (OR = 1.44, 95%CI = 1.04–2.01), smoking duration (OR = 1.53, 95%CI = 1.07–2.18) and pack-years (OR = 1.56, 95%CI = 1.10–2.22). For never smokers, FL risk increased for those exposed indoors to >2 smokers during childhood (OR = 1.84, 95%CI = 1.11–3.04). For cas...
Lancet (London, England), Jun 6, 2017
Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of ... more Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. In this international, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously treated. Patients were enrolled across 52 centres in 13 countries. Patients were randomly assigned (1:1) centrally by an interactive voice and web response system to receive intravenous brentuximab vedotin 1·8 mg/kg once every 3 weeks, for up to 16 3-week cycles, or physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m(2) once per day) for up to 48 weeks. The primary endpoint was the proportion ...
Journal of the National Cancer Institute, Jun 1, 2017
European Journal of Cancer, 2020
Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-... more Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 mg/kg once every 3 weeks; 16 cycles) versus physician's choice (methotrexate/bexarotene; 48 weeks) in the phase III ALCANZA study. Quality of life (QoL) in ALCANZA patients was also examined. Methods: QoL measures in ALCANZA were based on the Skindex-29, Functional Assessment of Cancer Therapy-General (FACT-G) and European QoL 5-dimension (EQ-5D) questionnaires. Results: Mean maximum reduction from the baseline Skindex-29 symptom domain score (key secondary end-point) was greater with brentuximab vedotin than physician's choice (-27.96 versus-8.62); the difference,-18.9 (95% confidence interval-26.6,-11.2; adjusted p < 0.001), exceeded the study-defined minimally important difference (9.0-12.3). Mean changes from baseline to endof-treatment visit total FACT-G scores were similar with brentuximab vedotin and physician's choice (0.15 versus-2.29). EQ-5D changes were also comparable between arms. Among brentuximab vedotin-treated patients with peripheral neuropathy (PN), mean maximum reduction in Skindex-29 symptom domain was-35.54 versus-11.11 in patients without PN. PN had no meaningful effect on FACT-G and EQ-5D QoL scores. Conclusions: In summary, brentuximab vedotin produced superior reductions in symptom burden compared with physician's choice, without adversely impacting QoL. QoL was unaffected by the presence of PN in brentuximab vedotin-treated patients. Clinical trial registration: NCT01578499.
Cell & Gene Therapy, 2004
Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphopenia
Leukemia & Lymphoma, 2001
We describe a unique case of a patient with a three-year history of idiopathic CD4(+) T cell lymp... more We describe a unique case of a patient with a three-year history of idiopathic CD4(+) T cell lymphopenia (HIV negative) who presented with stage IV diffuse large cell non Hodgkin's lymphoma with t(8;22). Despite the severe lymphopenia, the patient tolerated intensive chemotherapy well and at 18 months, remains in complete remission.
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
PLoS pathogens, 2014
Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells i... more Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important in maintaining HIV latency and histone deacetylase inhibitors (HDACi) may reverse latency by activating HIV transcription from latently infected CD4+ T-cells. We performed a single arm, open label, proof-of-concept study in which vorinostat, a pan-HDACi, was administered 400 mg orally once daily for 14 days to 20 HIV-infected individuals on suppressive antiretroviral therapy (ART). The primary endpoint was change in cell associated unspliced (CA-US) HIV RNA in total CD4+ T-cells from blood at day 14. The study is registered at ClinicalTrials.gov (NCT01365065). Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations. CA-US HIV RNA in blood increased significantly in 18/20 patients (90%) with a median fold change from baseline to peak value of 7.4 (IQR 3.4...
Role of radiotherapy in solitary bone plasmacytomas
Asia-Pacific Journal of Clinical Oncology, 2005
Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment rem... more Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment remains local radiotherapy (RT). While this results in high rates of local control, the majority of patients ultimately develop multiple myeloma (MM). Here we present a 20-year ...
Fluorine 18 fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of three patients with vasculitis
The American Journal of Medicine, 2004
Short title: Advanced-stage CTCL and large cell transformation
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
Blood Reviews, 2009
... Edward A. Stadtmauer 1 ,; Donna M. Weber 2 ,; Ruben Niesvizky 3 ,; Andrew Belch 4 ,; Miles H.... more ... Edward A. Stadtmauer 1 ,; Donna M. Weber 2 ,; Ruben Niesvizky 3 ,; Andrew Belch 4 ,; Miles H. Prince 5 ,; Jesús F. San Miguel 6 ,; Thierry Facon 7 ... Correspondence: Dr Edward A ... Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma ...
Role of radiotherapy in solitary bone plasmacytomas
Asia-Pacific Journal of Clinical Oncology, 2005
Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment rem... more Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment remains local radiotherapy (RT). While this results in high rates of local control, the majority of patients ultimately develop multiple myeloma (MM). Here we present a 20-year ...
The American Journal of Medicine, 2004
The diagnosis of spine infections can be difficult, because the patient's history, subjective sym... more The diagnosis of spine infections can be difficult, because the patient's history, subjective symptoms and physical findings are often inconclusive, particularly in the early stages. Nuclear medicine procedures, which identify pathophysiological reactions preceding morphological changes, can play a useful role in the diagnosis of spondylodiscitis. Specific tracers are used in infectious bone disease: Ga-67, Tc-99m nanocolloid, Tc-99m-HMPAO-and In-111-labeled leukocytes, Tc-99m and In-111 polyclonal human immunoglobulin, and Tc-99m-labeled monoclonal antibodies . However, for diagnosing spine infections, these procedures are still not optimal [10, 19]. On white cell imaging, up to 50% of all patients with spondylodiscitis show photopoenic defects, which are not specific for infection .
Journal of the American Academy of Dermatology, 2007
Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent r... more Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis. ( J Am Acad Dermatol
Cancers
The association between smoking and alcohol consumption and follicular lymphoma (FL) incidence an... more The association between smoking and alcohol consumption and follicular lymphoma (FL) incidence and clinical outcome is uncertain. We conducted a population-based family case-control study (709 cases: 490 controls) in Australia. We assessed lifetime history of smoking and recent alcohol consumption and followed-up cases (median = 83 months). We examined associations with FL risk using unconditional logistic regression and with all-cause and FL-specific mortality of cases using Cox regression. FL risk was associated with ever smoking (OR = 1.38, 95%CI = 1.08–1.74), former smoking (OR = 1.36, 95%CI = 1.05–1.77), smoking initiation before age 17 (OR = 1.47, 95%CI = 1.06–2.05), the highest categories of cigarettes smoked per day (OR = 1.44, 95%CI = 1.04–2.01), smoking duration (OR = 1.53, 95%CI = 1.07–2.18) and pack-years (OR = 1.56, 95%CI = 1.10–2.22). For never smokers, FL risk increased for those exposed indoors to >2 smokers during childhood (OR = 1.84, 95%CI = 1.11–3.04). For cas...
Lancet (London, England), Jun 6, 2017
Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of ... more Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. In this international, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously treated. Patients were enrolled across 52 centres in 13 countries. Patients were randomly assigned (1:1) centrally by an interactive voice and web response system to receive intravenous brentuximab vedotin 1·8 mg/kg once every 3 weeks, for up to 16 3-week cycles, or physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m(2) once per day) for up to 48 weeks. The primary endpoint was the proportion ...
Journal of the National Cancer Institute, Jun 1, 2017
European Journal of Cancer, 2020
Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-... more Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 mg/kg once every 3 weeks; 16 cycles) versus physician's choice (methotrexate/bexarotene; 48 weeks) in the phase III ALCANZA study. Quality of life (QoL) in ALCANZA patients was also examined. Methods: QoL measures in ALCANZA were based on the Skindex-29, Functional Assessment of Cancer Therapy-General (FACT-G) and European QoL 5-dimension (EQ-5D) questionnaires. Results: Mean maximum reduction from the baseline Skindex-29 symptom domain score (key secondary end-point) was greater with brentuximab vedotin than physician's choice (-27.96 versus-8.62); the difference,-18.9 (95% confidence interval-26.6,-11.2; adjusted p < 0.001), exceeded the study-defined minimally important difference (9.0-12.3). Mean changes from baseline to endof-treatment visit total FACT-G scores were similar with brentuximab vedotin and physician's choice (0.15 versus-2.29). EQ-5D changes were also comparable between arms. Among brentuximab vedotin-treated patients with peripheral neuropathy (PN), mean maximum reduction in Skindex-29 symptom domain was-35.54 versus-11.11 in patients without PN. PN had no meaningful effect on FACT-G and EQ-5D QoL scores. Conclusions: In summary, brentuximab vedotin produced superior reductions in symptom burden compared with physician's choice, without adversely impacting QoL. QoL was unaffected by the presence of PN in brentuximab vedotin-treated patients. Clinical trial registration: NCT01578499.
Cell & Gene Therapy, 2004
Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphopenia
Leukemia & Lymphoma, 2001
We describe a unique case of a patient with a three-year history of idiopathic CD4(+) T cell lymp... more We describe a unique case of a patient with a three-year history of idiopathic CD4(+) T cell lymphopenia (HIV negative) who presented with stage IV diffuse large cell non Hodgkin's lymphoma with t(8;22). Despite the severe lymphopenia, the patient tolerated intensive chemotherapy well and at 18 months, remains in complete remission.
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
PLoS pathogens, 2014
Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells i... more Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important in maintaining HIV latency and histone deacetylase inhibitors (HDACi) may reverse latency by activating HIV transcription from latently infected CD4+ T-cells. We performed a single arm, open label, proof-of-concept study in which vorinostat, a pan-HDACi, was administered 400 mg orally once daily for 14 days to 20 HIV-infected individuals on suppressive antiretroviral therapy (ART). The primary endpoint was change in cell associated unspliced (CA-US) HIV RNA in total CD4+ T-cells from blood at day 14. The study is registered at ClinicalTrials.gov (NCT01365065). Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations. CA-US HIV RNA in blood increased significantly in 18/20 patients (90%) with a median fold change from baseline to peak value of 7.4 (IQR 3.4...
Role of radiotherapy in solitary bone plasmacytomas
Asia-Pacific Journal of Clinical Oncology, 2005
Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment rem... more Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment remains local radiotherapy (RT). While this results in high rates of local control, the majority of patients ultimately develop multiple myeloma (MM). Here we present a 20-year ...
Fluorine 18 fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of three patients with vasculitis
The American Journal of Medicine, 2004
Short title: Advanced-stage CTCL and large cell transformation
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
Blood Reviews, 2009
... Edward A. Stadtmauer 1 ,; Donna M. Weber 2 ,; Ruben Niesvizky 3 ,; Andrew Belch 4 ,; Miles H.... more ... Edward A. Stadtmauer 1 ,; Donna M. Weber 2 ,; Ruben Niesvizky 3 ,; Andrew Belch 4 ,; Miles H. Prince 5 ,; Jesús F. San Miguel 6 ,; Thierry Facon 7 ... Correspondence: Dr Edward A ... Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma ...
Role of radiotherapy in solitary bone plasmacytomas
Asia-Pacific Journal of Clinical Oncology, 2005
Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment rem... more Background: Solitary bone plasmacytoma (SBP) is a rare tumor for which the standard treatment remains local radiotherapy (RT). While this results in high rates of local control, the majority of patients ultimately develop multiple myeloma (MM). Here we present a 20-year ...
The American Journal of Medicine, 2004
The diagnosis of spine infections can be difficult, because the patient's history, subjective sym... more The diagnosis of spine infections can be difficult, because the patient's history, subjective symptoms and physical findings are often inconclusive, particularly in the early stages. Nuclear medicine procedures, which identify pathophysiological reactions preceding morphological changes, can play a useful role in the diagnosis of spondylodiscitis. Specific tracers are used in infectious bone disease: Ga-67, Tc-99m nanocolloid, Tc-99m-HMPAO-and In-111-labeled leukocytes, Tc-99m and In-111 polyclonal human immunoglobulin, and Tc-99m-labeled monoclonal antibodies . However, for diagnosing spine infections, these procedures are still not optimal [10, 19]. On white cell imaging, up to 50% of all patients with spondylodiscitis show photopoenic defects, which are not specific for infection .
Journal of the American Academy of Dermatology, 2007
Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent r... more Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis. ( J Am Acad Dermatol